Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients

Table 2 Type and line of therapy, treatment response and CTCs results before and during the course of therapy from 33 colorectal cancer patients

PatientID	Therapy	Line of therapy	Staging outcome	CTCs before therapy	CTCs during therapy
PatientID	Therapy	Line of therapy	Staging outcome	CTCs before therapy	1–4 weeks	5–8 weeks	9–12 weeks
5	FOLFIRI+Beva	2	PD	+	-	-	+
7	FUFOX	2	PD	+	+	+	+
8	FOLFIRI+Beva	2	NP	+	+	+	-
9	FUFIRI	2	PD	+	+	+	+
15	FOLFIRI	1	PD	-	+	+	+
36	FOLFOX-4	1	PD	+	-	+	+
39	FUFIRI	2	PD	+	-	-	-
47	FOLFIRI+Beva	1	NP	+	-	-	-
49	FOLFOX-4	1	NP	+	-	+	-
49	FOLFIRI	2	PD	+	+	+	+
65	Panitumumab	2	NP	-	-	+	-
65	Panitumumab	2	PD	+	+	+	+
70	FOLFOX-4	1	NP	-	-	+	-
73	FOLFOX-4	1	PD	+	-	-	+
74	FOLFIRI+Beva	2	PD	+	+	+	+
77	AIO+Beva	1	NP	+	+	+	-
80	FOLFIRI+Beva	1	NP	-	-	-	-
81	FUFIRI	1	PD	-	+	+	+
81	FUFOX	2	PD	+	+	+	+
87	AIO	1	NP	+	-	-	+
91	AIO +Beva	2	NP	-	-	-	-
97	FOLFIRI +Beva	1	NP	+	+	+	+
97	FOLFIRI +Beva	1	PD	+	+	+	-
99	FOLFOX-4	1	NP	-	-	-	-
109	AIO	1	PD	+	+	+	+
112	FOLFIR+Beva	1	NP	-	+	-	-
139	FOLFIR+Beva	1	NP	+	+	-	-
150	AIO +Beva	1	NP	-	-	-	-
151	FUFOX	1	NP	+	+	-	+
151	FUFOX	1	PD	+	+	+	+
171	FOLFOX-4	1	NP	+	-	-	-
184	AIO	1	NP	-	-	-	-
195	AIO	1	PD	+	+	+	+

ISSN: 1479-5876